See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $120B | 10.0x | 22.2x | |
| $10.6B | 3.3x | 14.3x | |
| $7.3B | 18.8x | 43.5x | |
| $5.1B | 1481.3x | -308.6x | |
| $4.7B | 7.4x | 43.9x | |
| $3.3B | 413.0x | -5.9x | |
| $2.2B | 31.1x | -67.3x | |
| $2.1B | 5.6x | 12.7x | |
| $1.9B | 51.1x | -4.0x | |
| $1.8B | 6.5x | 25.3x | |
| $1.7B | 7.6x | 60.7x | |
| $1.5B | n/a | n/a | |
| $1.1B | 1736.4x | -11.0x | |
| $1.0B | n/a | -39.5x | |
| $963M | 17.0x | -2.2x | |
| $652M | n/a | n/a | |
| $650M | 41.2x | -3.8x | |
| $637M | 1.6x | 6.3x | |
| $584M | 1.1x | 10.0x | |
| $473M | 421.9x | n/a | |
| $417M | 12.9x | n/a | |
| $363M | n/a | -1.0x | |
| $344M | 34.8x | -9.6x | |
| $285M | 23.1x | -83.2x | |
| $237M | 12.2x | n/a | |
| $205M | 75.1x | n/a | |
| $176M | 6.5x | 19.4x | |
| $162M | 2.8x | 41.8x | |
| $157M | n/a | -0.7x | |
| $157M | 18.9x | -26.3x | |
| $123M | 1.2x | -0.8x | |
| $117M | 1.1x | 71.9x | |
| $103M | n/a | n/a | |
| $95.4M | n/a | n/a | |
| $73.5M | 3.9x | -8.3x | |
| $73.5M | n/a | n/a | |
| $63.0M | n/a | -5.1x | |
| $59.5M | 618.1x | n/a | |
| $59.4M | n/a | n/a | |
| $57.0M | 17.6x | -8.1x | |
| $28.4M | n/a | n/a | |
| $18.9M | n/a | n/a | |
| $18.4M | 35.8x | -0.1x | |
| $14.3M | 0.7x | n/a | |
| $3.5M | 3.6x | n/a | |
| $3.0M | 0.7x | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine